Genomic Convergence - Early Applications

Early Applications

In January 2003, Michael Hauser along with fellow researchers at the Duke Center for Human Genetics (CHG) coined the term “genomic convergence” to describe their endeavor to identify genes affecting the expression of Parkinson disease (PD). Their work successfully combined serial analysis of gene expression (SAGE) with genetic linkage analysis. The authors explain, “While both linkage and expression analyses are powerful on their own, the number of possible genes they present as candidates for PD or any complex disorder remains extremely large”. The convergence of the two methods allowed researchers to decrease the number of possible PD genes to consider for further study.

Their success prompted further use of the genomic convergence method at the CHG, and in July 2003 Yi-Ju Li, et al. published a paper revealing that glutathione S-transferase omega-1 (GSTO1) modifies the age-at-onset (AAO) of Alzheimer disease (AD) and PD.

In May 2004, Dr. Margaret Pericak-Vance, currently the director of the John P. Hussman Institute for Human Genomics at the University of Miami Miller School of Medicine and then the director of the CHG, articulated the value of the genomic convergence method at a New York Academy of Sciences (NYAS) keynote address entitled "Novel Methods in Genetic Exploration of Neurodegenerative Disease." She stated, "No single method is going to get us where we need to be with these complex traits. It is going to take a combination of methods to dissect the underlying etiology of these disorders".